Perspectives on the Treatment of Mantle Cell Lymphoma and Follicular Lymphoma in 2015 and Beyond

Summary of presentations from the Celgene satellite symposium, held at the 20th Congress of the European Hematology Association (EHA), Vienna, Austria, on 11th June 2015

Chairpersons: Martin Dreyling,1 Gilles Salles2
Speakers: Paolo Corradini,3 Jehan Dupuis,4 Steven Le Gouill,5 Marek Trněný6

1. Hospital of the Ludwig Maximilians University, Munich, Germany
2. Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Lyon, France
3. IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy
4. Centre Hospitalier Universitaire Henri Mondor, Créteil, France
5. Centre Hospitalier Universitaire de Nantes, Nantes, France
6. Charles University and General University Hospital, Prague, Czech Republic

Disclosure: All the authors have been advisers and/or speakers for Celgene. Martin Dreyling has received research and grant support from Celgene, Janssen, Mundipharma, Pfizer, and Roche as well as honoraria and consultancy fees from these companies. He has also received honoraria and consultancy fees from Gilead and has participated in advisory boards for Bayer, Celgene, Gilead, and Janssen. Paolo Corradini has received honoraria and consultancy fees from Sanofi, Celgene, Novartis, Takeda, Janssen, and Servier, and has participated in advisory boards for Celgene, Novartis, and Sanofi. Jehan Dupuis has received honoraria and consultancy fees from Celgene. Steven Le Gouill has received research and grant support from Roche and Janssen, honoraria and consultancy fees from Celgene, Janssen, Roche, Mundipharma, and Gilead, and has participated in advisory boards for Roche, Janssen, Gilead, and Celgene. Marek Trněný has received research and grant support from Roche and Celgene, honoraria and consultancy fees from Roche, Celgene, Gilead, and Janssen, and has participated in advisory boards for Roche and Celgene. Gilles Salles has declared no relevant disclosures.
Acknowledgements: Writing assistance was provided by Dr Juliet Bell of apothecom scopemedical Ltd.
Support: The symposium and medical writing assistance was funded by Celgene. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of Celgene.
Citation: EMJ Hema. 2015;3[1]:54–64.

Meeting Summary

Prof Martin Dreyling opened the symposium by providing an overview of the current status of mantle cell lymphoma (MCL) and the current guidelines for treatment. Prof Steven Le Gouill discussed emerging tools to improve the diagnosis and monitoring of patients such as the assessment of minimal residual disease and the optimal incorporation of new technologies into the treatment pathway. Prof Marek Trněný then spoke about new treatment options for MCL and the improved survival that has been reported from certain combination therapies. Prof Martin Dreyling closed the MCL session.

Prof Gilles Salles introduced the follicular lymphoma (FL) session by explaining how the treatment landscape of FL has recently changed with the advent of anti-CD20 therapies. Prof Paulo Corradini then described the current treatment landscape in FL and Dr Jehan Dupuis spoke about the use of positron emission tomography (PET) at the start, interim, and end of treatment for FL. Prof Gilles Salles described the challenges of incorporating new treatment recommendations and tools for FL within current treatment options, and then summarised and closed the event.

Download (PDF, 245KB)

Comments are closed.